Production & Manufacturing

Shilpa Biologicals Ltd, a subsidiary of Shilpa Medicare Ltd, has officially commissioned an advanced integrated Antibody–Drug Conjugate (ADC) GMP manufacturing site in Dharwad. Announced on 25 June 2026, the facility was specifically engineered to satisfy the rigorous global regulatory...

CPHI Milan 2026, recognized as a premier global gathering for the pharmaceutical industry, has announced the introduction of four new specialist zones for pharma at its upcoming event. Scheduled for October 6-8, 2026, at the Fiera Milan exhibition centre...

We are currently standing at the threshold of a medical revolution, transitioning from a model of managing chronic conditions to one of potentially curing genetic diseases at their foundational level. The promise of advanced therapeutics such as CRISPR-based gene...

Continuous manufacturing drug formulation represents the most significant leap in pharmaceutical engineering in over a century, fundamentally altering how medications are conceived, developed, and delivered to the global market. For decades, the industry operated under the batch manufacturing paradigm,...

Shilpa Biologicals Pvt. Ltd. (SBPL) has introduced PartnerPower Platform, a proprietary digital transparency solution designed to provide global sponsors with continuous, real-time visibility across biologics development and manufacturing activities. Announced on 22 June 2026 from Dharwad, India, the platform...

Eisai is moving ahead with a major upgrade of its manufacturing facility in Hatfield, Hertfordshire, backed by support from the United Kingdom’s Life Sciences Innovative Manufacturing Fund (LSIMF). The Japanese drugmaker is investing approximately 48 million pounds sterling ($64.5...

Recipharm has unveiled a multi-million-dollar investment in its US operations aimed at increasing sterile fill and finish manufacturing capacity for biologics and advanced therapies. The expansion comes after the company secured a clinical biologics fill and finish agreement with...